Hemab Seeks $212 Million in US IPO

Novo-backed Hemab Therapeutics, a clinical-stage biotechnology firm, is aiming to raise up to $212 million through an initial public offering in the United States. This move signals the company's intent to access public markets for further funding to advance its therapeutic pipeline. The IPO will provide capital for Hemab's ongoing research and development efforts, potentially accelerating the delivery of its innovative treatments to patients.